Legend Biotech (LEGN) FCF Margin (2019 - 2026)
Legend Biotech (LEGN) posted quarterly FCF Margin of 30.35% for Q1 2026, up 2380.0% year-on-year from 1.22% in Q1 2025, and down 662.0% on a QoQ basis from 3.98% in Q4 2025.
Legend Biotech (LEGN) FCF Margin (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has reported FCF Margin for 8 consecutive years, with 30.35% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin rose 2380.0% year-over-year to 30.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.23% (up 3382.0% YoY) and the FY2025 annual result came in at 9.74%, up 1547.0% from the prior year.
- FCF Margin retreated to 30.35% in Q1 2026 per LEGN's latest filing, from 3.98% in the prior quarter.
- Over the last five years, FCF Margin for LEGN reached as high as 94.39% in Q2 2022 and fell as low as 371.37% in Q1 2023.
- A 5-year average of 67.71% and a median of 47.56% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin tumbled 22889 bps — and 2024, when it soared 39452 bps.
- Year by year, FCF Margin stood at 104.28% in 2022, then soared by 100 bps to 0.17% in 2023, then slumped by 34880 bps to 57.87% in 2024, then soared by 93 bps to 3.98% in 2025, then sank by 662 bps to 30.35% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 30.35%, 3.98%, and 12.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Legend Biotech | 8.69 Bn | 7.79 Bn | 129.70 Mn | -30.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.35% |
| Dec 31, 2025 | -3.98% |
| Sep 30, 2025 | 12.41% |
| Jun 30, 2025 | 0.01% |
| Mar 31, 2025 | -54.15% |
| Dec 31, 2024 | -57.87% |
| Sep 30, 2024 | -47.56% |
| Jun 30, 2024 | -1.04% |
| Mar 31, 2024 | 23.15% |
| Dec 31, 2023 | -0.17% |
| Sep 30, 2023 | -63.81% |
| Jun 30, 2023 | -134.50% |
| Mar 31, 2023 | -371.37% |
| Dec 31, 2022 | -104.28% |
| Sep 30, 2022 | -254.14% |
| Jun 30, 2022 | 94.39% |
| Mar 31, 2022 | -157.76% |
| Dec 31, 2021 | -400.74% |
| Sep 30, 2021 | -274.61% |
| Jun 30, 2021 | -295.59% |